Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

5.000 +0.060 (+1.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats
From Vir Biotechnology, Inc.
Via GlobeNewswire
Biden's Urgent Action Against Antibiotic-Resistant Bacteria - Allocates $100M to Battle Deadly Superbugs
U.S. President Joe Biden is set to unveil a $100 million research initiative to tackle the growing threat of drug-resistant bacteria.  More than a million people worldwide succumb to infections caused... 
Via Benzinga
Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV
From Vir Biotechnology, Inc.
Via GlobeNewswire
What 8 Analyst Ratings Have To Say About Vir Biotechnology
 
Via Benzinga
Is Vir Biotechnology Stock a Buy?
The biotech is out to prove that it isn't just a "pandemic stock." 
Via The Motley Fool
Earnings Scheduled For August 3, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. 
Via Benzinga
Where Vir Biotechnology Stands With Analysts
 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During the session on Thursday, 461 stocks hit new 52-week lows. 
Via Benzinga
Why Vir Biotechnology Stock Is Plunging Today?
Vir Biotechnology Inc (NASDAQ: VIR) shares are tumbling after the company released data from the Phase 2 PENINSULA evaluating VIR-2482 to prevent  
Via Benzinga
Infectious Disease Player Vir Biotech Has Limited Near Term Upside, Analyst Downgrades
BofA Securities has downgraded Vir Biotechnology Inc (NASDAQ: VIR) to Neutral from Buy with a price target of $14,  
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 225 companies set new 52-week lows. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2023
 
Via Benzinga
Planet Labs PBC, GameStop And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures traded lower this morning on Friday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday morning, 164 companies achieved new lows for the year. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 283 companies set new 52-week lows. 
Via Benzinga
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology to Provide Business Update and Report Second Quarter 2023 Financial Results on August 3, 2023
From Vir Biotechnology, Inc.
Via GlobeNewswire
Microsoft, Snap, Texas Instruments And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures traded lower this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session. Snap Inc. (NYSE: SNAP) shares tumbled 18.6% to $10.18 in... 
Via Benzinga
Crude Oil Edges Higher; American Airlines Raises Profit Outlook
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling more than 250 points on Thursday. The Dow traded up 0.60% to 35,270.02 while the NASDAQ fell 1.89% to 14,086.02.... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's session, 40 stocks hit new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Why Infosys Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers PainReform Ltd. (NASDAQ: PRFX) jumped 45.5% to $10.34 after declining 8% on Wednesday. PaiReform recently regained compliance with Nasdaq continued listing requirements. 
Via Benzinga
Dow On Track For 9 Straight After Johnson & Johnson Earnings
The Dow Jones Industrial Average is looking to extend its win streak, last seen up 250 points as it paces for its ninth consecutive win. 
Via Talk Markets
Dow Surges 300 Points; Johnson & Johnson Posts Upbeat Earnings
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite declining over 1% on Thursday. The Dow traded up 0.87% to 35,365.00 while the NASDAQ fell 1.11% to 14,198.86. The S&P 500,... 
Via Benzinga
Why Shares of Vir Biotechnology Are Plunging Thursday
The company had disappointing trial news for one of its lead therapies. 
Via The Motley Fool
Nasdaq Down 50 Points; Tesla Earnings Beat Expectations
U.S. stocks traded mixed this morning, with the Dow Jones gaining over 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.40% to 35,202.41 while the NASDAQ fell 0.35% to... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer
From Vir Biotechnology, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.